IIL.AX -92%(!) on phase-2b failure in SPMS: http://www.innateimmuno.com/irm/PDF/1424_0/TopLineResultsforTrialofMIS416 Innate Immunotherapeutics Limited (ASX Code: IIL) today announced that its Phase 2B randomised, double-blind, placebo-controlled trial of the efficacy and safety of MIS416 in the treatment of subjects with secondary progressive multiple sclerosis (SPMS) did not show clinically meaningful or statistically significant differences in measures of neuromuscular function or patient reported outcomes.